Supplement-Drug treats penicillin-resistant CAP
Supplement-Drug treats penicillin-resistant CAP
Levaquin (levofloxacin tablets/injection) recently received a supplemental new drug application from the Food and Drug Adminis tra tion for the treatment of penicillin-resistant S. pneumoniae in community-acquired pneumonia (CAP), says its manufacturer Ortho-McNeil Pharmaceutical in Raritan, NJ. Data provided to the FDA demonstrated that Levaquin was effective in each of 15 cases of pneumonia caused by penicillin-resistant S. pneumoniae, including six cases with bacteremia.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.